STAT+: Struggling lobbyists, panicked clients: D.C. comes to grips with Trump’s second term
Trump's second term is playing out a lot differently than health care companies and their lobbyists hoped for.
WASHINGTON — After November’s election, many of the lobbyists and lawyers representing the health care industry expected a second Trump term would be much like the first: opportunities for regulatory trims, concerns about budget cuts, and more governing via social media.
But less than 100 days into President Trump’s administration, far more sweeping changes are materializing for the health care industry, creating unprecedented challenges for companies and their Washington lobbyists.
The changes go well beyond unfavorable policies. At risk are the foundational government systems the organizations rely on to carry out their missions — whether that’s developing drugs, treating patients, insuring Americans or supporting people diagnosed with particular diseases.
